Molecular diagnostics of acute intermittent porphyria
- PMID: 14995910
- DOI: 10.1586/14737159.4.2.243
Molecular diagnostics of acute intermittent porphyria
Abstract
Acute intermittent porphyria (AIP) is an inherited metabolic disease with an autosomal dominant pattern of inheritance. The disease is caused by a partial deficiency of porphobilinogen deaminase (PBGD) in heme biosynthesis. Since biochemical measurements of patients and their healthy relatives overlap, the diagnosis of AIP may remain undetermined at the symptom-free phase. Mutation detection in AIP, which provides 95% sensitivity and around 100% specificity, has quickly been incorporated into good clinical practice. During an acute attack, which includes various neurovisceral symptoms, measurement of urinary porphobilinogen (PBG) is a method of choice to confirm diagnosis, and DNA testing is unnecessary at that stage. DNA testing has revealed many new patients and excluded AIP from many healthy relatives despite slightly increased excretions of porphyrin precursors and erythrocyte PBGD in the low or borderline zone. Thus, quality-assured DNA testing is accurate enough to confirm or exclude the diagnosis of AIP. The clinical utility of DNA testing is limited for those individuals whose mutation is currently unknown, in which biochemical analyses are essential and the majority of the patients can be identified using urinary PBG and erythrocyte PBGD measurements. The measurement of urinary PBG can be used to evaluate the prognosis for symptom-free individuals. Currently, DNA testing of AIP at the population level is not recommended unless the frequency of gene carriers is locally very high and large-scale population-based mutation screening is reasonable. In the future, the knowledge of gene-gene and gene-environment interactions and protein networks using gene array and proteomics technologies may provide more precise information about pathogenetic mechanisms and novel therapeutic strategies for an acute attack and the long-term complications of AIP. Increasing knowledge of pharmacogenetics may identify the patients who are at high risk for clinical manifestations.
Copyright Future Drugs Ltd.
Similar articles
-
Acute intermittent porphyria in childhood: a population-based study.Acta Paediatr. 2003 May;92(5):562-8. Acta Paediatr. 2003. PMID: 12839285
-
Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.Eur J Intern Med. 2009 Mar;20(2):201-7. doi: 10.1016/j.ejim.2008.06.012. Epub 2008 Aug 8. Eur J Intern Med. 2009. PMID: 19327613 Clinical Trial.
-
Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.Clin Chem. 2002 Nov;48(11):1891-900. Clin Chem. 2002. PMID: 12406973
-
Acute Intermittent Porphyria.2005 Sep 27 [updated 2024 Feb 8]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2005 Sep 27 [updated 2024 Feb 8]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301372 Free Books & Documents. Review.
-
Acute intermittent porphyria: laboratory diagnosis by molecular methods.Clin Lab Med. 1995 Dec;15(4):943-56. Clin Lab Med. 1995. PMID: 8838232 Review.
Cited by
-
The acute porphyrias: a diagnostic and therapeutic challenge in internal and emergency medicine.Intern Emerg Med. 2009 Aug;4(4):297-308. doi: 10.1007/s11739-009-0261-4. Epub 2009 May 29. Intern Emerg Med. 2009. PMID: 19479318
-
Clinical feature and genetic analysis of HMBS gene in Chinese patients with acute intermittent porphyria: a systematic review.Front Genet. 2023 Dec 11;14:1291719. doi: 10.3389/fgene.2023.1291719. eCollection 2023. Front Genet. 2023. PMID: 38148975 Free PMC article.
-
An update of clinical management of acute intermittent porphyria.Appl Clin Genet. 2015 Sep 1;8:201-14. doi: 10.2147/TACG.S48605. eCollection 2015. Appl Clin Genet. 2015. PMID: 26366103 Free PMC article. Review.
-
Biochemical compared to molecular diagnosis in acute intermittent porphyria.J Inherit Metab Dis. 2006 Feb;29(1):157-61. doi: 10.1007/s10545-006-0155-9. J Inherit Metab Dis. 2006. PMID: 16601882
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous